OKYO Pharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bob Dempsey

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	less than a year
Board average tenure	4.2yrs

Recent management updates

Recent updates

OKYO Pharma Limited (NASDAQ:OKYO) Shares Could Be 40% Below Their Intrinsic Value Estimate

Jan 11

CEO

Bob Dempsey

less than a year

Tenure

Mr. Robert J. Dempsey M.B.A., also known as Bob, is Independent Chairman of the Board of Azalea Vision BV. He was an Interim Chief Executive Officer of Ashvattha Therapeutics, Inc. from October 14, 2025 to...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Gary Jacob	Chief Development Officer & Director	less than a year	US$678.00k	0.089% $ 80.2k
Robert Dempsey	CEO & Executive Director	less than a year	no data	no data
Michael Beck	Founder	no data	no data	no data
Keeren Shah	Chief Financial Officer	5.5yrs	no data	no data
Rajkumar Patil	Chief Scientific Officer	4.9yrs	no data	no data
Flavio Mantelli	Chief Medical Officer	no data	no data	no data

0.08yrs

Average Tenure

67yo

Average Age

Experienced Management: OKYO's management team is not considered experienced ( 0.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Gary Jacob	Chief Development Officer & Director	5.1yrs	US$678.00k	0.089% $ 80.2k
Robert Dempsey	CEO & Executive Director	less than a year	no data	no data
Bernard Denoyer	Independent Non-Executive Director	4.2yrs	US$51.00k	0% $ 0
Gabriele Marco Cerrone	Non-Executive Chairman	5.1yrs	US$922.00k	19.8% $ 17.8m
John Brancaccio	Independent Non-Executive Director	5.7yrs	US$85.00k	0% $ 0
Jay Pepose	Member of Scientific Advisory Board	3yrs	no data	no data
Willy Simon	Senior Independent Non-Executive Director	10.3yrs	US$76.00k	0.017% $ 15.7k
Napoleone Ferrara	Member of Scientific Advisory Board	5.5yrs	no data	no data
Pedram Hamrah	Member of Scientific Advisory Board	no data	no data	no data
Victor Perez	Member of Scientific Advisory Board	2.1yrs	no data	no data
Anat Galor	Member of Scientific Advisory Board	2.1yrs	no data	no data
Mark Milner	Member of Scientific Advisory Board	2.1yrs	no data	no data

4.2yrs

Average Tenure

74yo

Average Age

Experienced Board: OKYO's board of directors are considered experienced (4.2 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/15 03:14
End of Day Share Price	2026/02/13 00:00
Earnings	2025/09/30
Annual Earnings	2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OKYO Pharma Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
William Wood	B. Riley Securities, Inc.
Yi Chen	H.C. Wainwright & Co.
Elemer Piros	Lucid Capital Markets

OKYO Pharma Management

Management criteria checks 1/4

Key information

Recent management updates

High number of new directors

Okyo Pharma Limited Announces Transition of Gary S. Jacob, Ph.D. to Chief Development Officer, Effective January 5, 2026

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer, Effective September 1, 2023

Recent updates

New major risk - Shareholder dilution

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $20.00775 million.

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Shareholder dilution

High number of new directors

OKYO Pharma Limited Announces Successful Type C Meeting with the FDA

FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain

OKYO Pharma Limited (NASDAQ:OKYO) Shares Could Be 40% Below Their Intrinsic Value Estimate

Okyo Pharma Limited Announces Transition of Gary S. Jacob, Ph.D. to Chief Development Officer, Effective January 5, 2026

OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain

New major risk - Revenue and earnings growth

OKYO Pharma Limited Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

Price target increased by 17% to US$7.00

OKYO Pharma Limited Announces Plans to Accelerate the Clinical Development of Urcosimod to Treat Neuropathic Corneal Pain

Okyo Pharma Files for Fast Track Designation with Fda for Urcosimod to Treat Neuropathic Corneal Pain

OKYO Pharma Limited announced that it has received $1.4 million in funding

OKYO Pharma Limited Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain

OKYO Pharma Limited announced delayed 20-F filing

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101

Okyo Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain

OKYO Pharma Limited Announces Appointment of Scientific Advisory Board

OKYO Pharma Limited Reports Positive Safety and Efficacy Results in Its Phase 2, Randomized, Double-Masted, Placebo-Controlled Trial Evaluating the Safety and Efficacy of OK-101 Ophthalmic Solution in Patients with Dry Eye Disease

OKYO Pharma Limited has filed a Follow-on Equity Offering in the amount of $4 million.

Okyo Pharma Limited Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit

OKYO Pharma Limited, Annual General Meeting, Dec 14, 2023

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $1.6389 million.

Okyo Pharma Limited Announces Filing of an Investigational New Drug (Ind) Application for Ok-101 to Treat Neuropathic Corneal Pain

OKYO Pharma Limited Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease (DED)

OKYO Pharma Limited has completed a Follow-on Equity Offering in the amount of $4.000005 million.

Okyo Pharma Limited Completes Enrollment in Phase 2 Clinical Trial of Ok-101 to Treat Dry Eye Disease